GO:0070888 E-box binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070888 (E-box binding) is a biological_process term describing the selective interaction of proteins with the DNA sequence motif CANNTG, known as the E-box.
• E-box binding is mediated by basic helix-loop-helix (bHLH) transcription factors such as MYC, MAX, CLOCK, BMAL1, and ZEB proteins, which regulate gene expression [1,3,6].
• Dysregulated E-box binding contributes to cancer, fibrosis, osteoarthritis, and immune disorders through altered transcriptional programs [1,2,4,5].
• The affinity and specificity of E-box binding depend on flanking sequences and partner proteins, influencing tissue-specific and circadian gene regulation [3,7].
• Experimental approaches to study E-box binding include chromatin immunoprecipitation, electrophoretic mobility shift assays, and CRISPR-based genome editing [3,6].
• Targeting E-box binding with small molecules or genetic tools offers therapeutic potential in oncology and inflammatory diseases.
Description
E-box binding (GO:0070888) is a fundamental biological process in which transcription factors recognize and bind to the E-box DNA motif (CANNTG), thereby regulating gene expression. This process is central to diverse cellular functions, including cell cycle control, differentiation, metabolism, and circadian rhythms [1,3]. The E-box was initially identified as a regulatory element in immunoglobulin genes, but subsequent research has revealed its widespread role in development and disease. Dysregulation of E-box binding is implicated in numerous pathologies, including cancer, fibrosis, and autoimmune conditions [1,2,5]. For example, MYC, a well-known bHLH transcription factor, binds E-boxes to drive oncogenic transcriptional programs, and its inhibition reduces tumor growth in xenograft models. Similarly, ZEB2, a zinc finger E-box binding protein, is critical for the formation of age-associated B cells, linking E-box binding to immune aging. Understanding the mechanisms, key genes, and regulatory networks of E-box binding is essential for researchers aiming to manipulate this process for therapeutic benefit. This article provides a comprehensive overview based on authoritative QuickGO data and verified PubMed literature, covering the definition, core mechanisms, key genes, disease associations, and experimental models for studying E-box binding.
E-box binding At A Glance
| GO ID | GO:0070888 |
|---|---|
| GO term | E-box binding |
| Ontology | biological_process |
| Synonym | None |
| Major function | Selective interaction with the E-box DNA motif (CANNTG) to regulate transcription |
| Key transcription factor families | bHLH (MYC, MAX, CLOCK, BMAL1), zinc finger (ZEB1, ZEB2) [1,2,3,6] |
| DNA motif | CANNTG (E-box) |
| Associated diseases | Cancer, fibrosis, osteoarthritis, immune disorders [1,2,4,5] |
| Research methods | ChIP-seq, EMSA, CRISPR screens, reporter assays [3,6] |
What Is GO:0070888?
E-box binding (GO:0070888) is defined as the biological process in which a protein selectively interacts with an E-box, a DNA sequence motif with the consensus CANNTG (where N is any nucleotide). This binding event typically occurs in the regulatory regions of genes and is mediated by transcription factors that contain a basic helix-loop-helix (bHLH) domain, which recognizes the E-box. The process is essential for transcriptional regulation, influencing gene expression in response to developmental, metabolic, and environmental cues [1,3].
Why Is E-box binding Important in Cell Biology?
E-box binding is a pivotal regulatory process that controls gene expression programs essential for normal development and homeostasis, and its dysregulation is a hallmark of many human diseases. Because E-box binding factors such as MYC and ZEB proteins are frequently altered in cancer and inflammatory conditions, understanding this process offers opportunities for targeted therapeutic intervention [1,2,6].
• Regulates cell proliferation, differentiation, and apoptosis through MYC and other bHLH factors.
• Controls circadian rhythms via CLOCK-BMAL1 binding to E-boxes in clock genes.
• Drives epithelial-to-mesenchymal transition (EMT) in fibrosis and cancer metastasis.
• Modulates immune cell development, including age-associated B cells.
• Contributes to osteoarthritis pathogenesis through ZEB2-mediated pathways.
• Protects against acute kidney injury via ZEB1-dependent autophagy.
• Serves as a target for small-molecule inhibitors like ME47 to reduce tumor growth.
• Influences tissue-specific gene expression through differential E-box affinity.
• Provides a mechanism for integrating metabolic and environmental signals into transcriptional output.
• Offers a rich source of biomarkers and therapeutic targets in oncology and regenerative medicine [1,6].
What Happens During E-box binding?
Recognition of the E-box motif
In simple terms: Transcription factors scan DNA and find the E-box sequence.
The process begins when a bHLH or zinc finger transcription factor recognizes the E-box consensus sequence CANNTG in the regulatory regions of target genes. This recognition is mediated by the basic region of the bHLH domain, which makes sequence-specific contacts with the DNA major groove. The binding affinity can vary depending on the flanking nucleotides and the presence of partner proteins, as shown for MYC/MAX complexes.
Dimerization and complex formation
In simple terms: Transcription factors pair up to bind DNA more effectively.
Most E-box binding proteins function as dimers. For example, MYC dimerizes with MAX to form a competent DNA-binding complex, while CLOCK partners with BMAL1 to regulate circadian genes [1,3]. Dimerization is mediated by the helix-loop-helix domain, which facilitates protein-protein interactions. The composition of the dimer influences target gene specificity and transcriptional activity.
Transcriptional activation or repression
In simple terms: Once bound, the factors turn genes on or off.
Upon binding to E-boxes, transcription factors recruit coactivators or corepressors to modulate RNA polymerase II activity. MYC/MAX complexes typically activate genes involved in cell growth and proliferation, whereas other complexes such as MAD/MAX can repress transcription. ZEB proteins can act as repressors or activators depending on context, influencing EMT and immune cell fate [2,5].
Integration of cellular signals
In simple terms: E-box binding responds to signals inside and outside the cell.
E-box binding is dynamically regulated by signaling pathways and environmental cues. For instance, the circadian clock components CLOCK and BMAL1 bind E-boxes in a rhythmic manner, coordinating gene expression with the day-night cycle. Growth factor signaling can alter MYC abundance and activity, thereby affecting E-box occupancy. This integration allows cells to adapt transcriptional programs to changing conditions.
Downstream effects on cell behavior
In simple terms: Gene expression changes lead to changes in cell function.
The ultimate outcome of E-box binding is altered expression of target genes that control cell cycle progression, metabolism, differentiation, and survival. For example, ZEB2-driven E-box binding promotes age-associated B cell formation, impacting immune responses. In fibrosis, ZEB1 stabilization enhances E-box-dependent EMT, contributing to tissue remodeling.
Key Genes Involved in GO:0070888 E-box binding
The following genes encode proteins that bind E-boxes and are frequently studied in the context of GO:0070888.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYC | bHLH transcription factor; binds E-boxes to activate growth-promoting genes | Oncogene; target for cancer therapy |
| MAX | bHLH partner of MYC; forms heterodimers for DNA binding | Modulates MYC target specificity |
| CLOCK | bHLH-PAS transcription factor; binds E-boxes with BMAL1 to regulate circadian genes | Circadian rhythm research |
| BMAL1 (ARNTL) | bHLH-PAS partner of CLOCK; essential for circadian E-box binding | Circadian biology and metabolism |
| ZEB1 | Zinc finger E-box binding homeobox 1; regulates EMT and autophagy [5,8] | Fibrosis, acute kidney injury [5,8] |
| ZEB2 | Zinc finger E-box binding homeobox 2; drives age-associated B cells and osteoarthritis [2,4] | Immunology, osteoarthritis [2,4] |
| MYCN | bHLH transcription factor; binds E-boxes in neuroblastoma | Pediatric cancer research |
| MITF | bHLH-Zip transcription factor; binds E-boxes in melanocytes | Melanoma and pigmentation |
| TCF3 (E2A) | bHLH transcription factor; regulates lymphocyte development | Immunology and leukemia |
| ID proteins | Dominant-negative bHLH proteins; inhibit E-box binding by sequestering partners | Development and cancer |
| HIF-1alpha | bHLH-PAS transcription factor; may bind E-box-like elements under hypoxia | Hypoxia and cancer metabolism |
| NPAS4 | bHLH-PAS transcription factor; binds E-boxes in neurons | Neurodevelopment and plasticity |
| DEC1 (BHLHE40) | bHLH transcription factor; binds E-boxes in circadian and immune regulation | Circadian and immune research |
| DEC2 (BHLHE41) | bHLH transcription factor; regulates sleep and circadian rhythms | Sleep disorders |
| SREBP1 | bHLH-Zip transcription factor; binds E-boxes in lipid metabolism genes | Metabolic disorders |
| USF1 | bHLH-Zip transcription factor; binds E-boxes in housekeeping genes | Cardiovascular genetics |
| TFAP4 | bHLH transcription factor; binds E-boxes in cancer | Oncology |
| MXD1 (MAD1) | bHLH-Zip transcription factor; antagonizes MYC at E-boxes | Cancer and differentiation |
How Is E-box binding Regulated?
E-box binding is regulated at multiple levels. The abundance and activity of E-box binding proteins are controlled by transcription, translation, and post-translational modifications such as phosphorylation and ubiquitination. For example, MYC stability is regulated by phosphorylation and degradation pathways, affecting its occupancy at E-boxes. Partner availability, such as MAX or BMAL1, also determines binding specificity and affinity [3,7]. Additionally, competitive inhibitors like ID proteins can sequester bHLH factors and prevent E-box binding. Signaling pathways, including growth factor and circadian inputs, modulate E-box binding dynamics to coordinate gene expression with cellular state [1,3].
E-box binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYC | Cancer (multiple types) | Xenograft models with MYC inhibition |
| ZEB1 | Pulmonary fibrosis, acute kidney injury [5,8] | Knockout or overexpression in fibrosis models [5,8] |
| ZEB2 | Osteoarthritis, age-associated B cells [2,4] | Rat osteoarthritis models, B cell differentiation assays [2,4] |
| CLOCK/BMAL1 | Circadian rhythm disorders | Tissue-specific knockout mice |
| MITF | Melanoma | Melanoma cell lines and mouse models |
E-box binding in cancer
Dysregulated E-box binding is a hallmark of many cancers. MYC overexpression leads to enhanced binding at E-boxes, driving uncontrolled proliferation and metabolic reprogramming. Small-molecule inhibition of MYC-E-box binding, such as with ME47, reduces tumor xenograft growth, highlighting the therapeutic potential of targeting this process. Other bHLH factors like MITF and MYCN also contribute to melanoma and neuroblastoma, respectively, through E-box-mediated transcriptional programs.
E-box binding in fibrosis and tissue remodeling
ZEB1 and ZEB2, which bind E-boxes, are key regulators of epithelial-to-mesenchymal transition (EMT), a process central to fibrosis and cancer metastasis. In pulmonary fibrosis, GTSE1-driven stabilization of ZEB1 promotes EMT through E-box-dependent gene expression. Conversely, ZEB2 alleviates osteoarthritis in rats, suggesting context-dependent roles. These findings underscore the importance of E-box binding in tissue remodeling and potential therapeutic targeting.
E-box binding in immune and inflammatory disorders
E-box binding factors influence immune cell development and function. ZEB2 drives the formation of age-associated B cells, which accumulate with age and contribute to autoimmunity. In acute kidney injury, ZEB1 activates autophagy and the AMPK/mTOR pathway, providing protection. These examples illustrate how E-box binding modulates immune and inflammatory responses, offering targets for intervention.
From E-box binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of E-box binding factor affect tumor growth? | Knockout of MYC or ZEB1 in cancer cell lines and xenografts [5,6] |
| What is the role of a specific E-box motif in gene regulation? | Point mutation of the E-box sequence in reporter constructs or endogenous loci |
| How does a disease-associated mutation alter E-box binding affinity? | Knock-in of mutant allele in cell lines or mice |
| Where does a transcription factor bind genome-wide? | Tagged knock-in of the factor followed by ChIP-seq |
| Can overexpression of an E-box factor drive a phenotype? | Overexpression of ZEB2 or MYC in primary cells or organoids [2,5] |
| What are the downstream targets of E-box binding? | RNA-seq after knockout or overexpression |
How to Study the E-box binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide binding sites of E-box factors | Mapping CLOCK-BMAL1 or MYC occupancy |
| EMSA | In vitro protein-DNA binding affinity | Validating E-box binding specificity |
| Reporter assay | Transcriptional activity from E-box promoters | Screening for inhibitors or activators |
| RNA-seq | Changes in gene expression upon E-box factor perturbation | Identifying downstream targets |
| CRISPR screen | Genes required for E-box-dependent phenotypes | Discovering synthetic lethal interactions |
| Proteomics | Protein interactions with E-box factors | Identifying cofactors and complexes |
| ATAC-seq | Chromatin accessibility at E-box regions | Assessing nucleosome positioning |
| Single-cell RNA-seq | Cell-to-cell variability in E-box target expression | Studying heterogeneity in tumors |
Chromatin immunoprecipitation (ChIP)
ChIP combined with sequencing (ChIP-seq) is the gold standard for mapping E-box binding sites across the genome. It involves crosslinking proteins to DNA, immunoprecipitating the factor of interest, and sequencing the bound DNA fragments. This method has been used to identify CLOCK-BMAL1 binding sites in a tissue-specific manner.
Electrophoretic mobility shift assay (EMSA)
EMSA is an in vitro technique to detect protein-DNA interactions. A labeled E-box probe is incubated with nuclear extracts or purified proteins, and the formation of protein-DNA complexes is visualized by gel electrophoresis. This assay can determine binding affinity and specificity, as demonstrated for MYC/MAX complexes.
Reporter assays
Reporter assays use a luciferase or fluorescent reporter driven by a promoter containing E-boxes. They measure the transcriptional activity of E-box binding factors in response to genetic or pharmacological perturbations. This approach is useful for screening inhibitors of E-box binding.
CRISPR-based screens
CRISPR knockout or activation screens can identify genes that regulate E-box binding or are required for its downstream effects. For example, a genome-wide screen could reveal modifiers of MYC-driven proliferation. These screens are powerful for discovering novel components of the E-box binding network.
How CRISPR Can Be Used to Study GO:0070888 E-box binding
Knockout
CRISPR knockout of E-box binding factor genes (e.g., MYC, ZEB1) is used to study loss-of-function phenotypes. For example, knockout of ZEB1 in cancer cell lines reduces EMT and migration. Knockout models help determine whether a factor is essential for a given process and can reveal compensatory mechanisms.
Point Mutation
Point mutations can be introduced into the DNA-binding domain of E-box factors to abrogate binding without affecting protein stability. This allows researchers to distinguish DNA-binding-dependent functions from other activities. Alternatively, point mutations in the E-box motif itself can be created to test its regulatory role.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into endogenous E-box factor loci enables ChIP-seq and imaging studies under native regulation. Knock-in of disease-associated mutations can model their impact on E-box binding and gene expression.
Overexpression
Overexpression of E-box factors such as MYC or ZEB2 is achieved by introducing a transgene or using CRISPR activation. This approach is used to study gain-of-function effects, including oncogenic transformation and immune cell differentiation [2,5]. Overexpression models are valuable for testing therapeutic inhibitors.
How EDITGENE Supports E-box binding Research
Researchers studying E-box binding-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, and CRISPR-based genome editing provides the tools to answer such questions with precision. EDITGENE offers a comprehensive suite of services to support these investigations.
Contact EDITGENE today to design your custom CRISPR model for E-box binding research.
Frequently Asked Questions About E-box binding
What is E-box binding?
E-box binding (GO:0070888) is the biological process in which proteins selectively interact with the E-box DNA motif (CANNTG) to regulate gene expression.
What genes are involved in E-box binding?
Key genes include MYC, MAX, CLOCK, BMAL1, ZEB1, ZEB2, and other bHLH or zinc finger transcription factors [1,2,3,5].
What diseases are associated with E-box binding?
Dysregulated E-box binding is linked to cancer, fibrosis, osteoarthritis, and immune disorders [1,2,4,5].
How can I study E-box binding in the lab?
Common methods include ChIP-seq, EMSA, reporter assays, and CRISPR-based screens [3,6].
What is the role of MYC in E-box binding?
MYC binds E-boxes as a heterodimer with MAX to activate genes that promote cell growth and proliferation [1,6].
How does CLOCK-BMAL1 bind E-boxes?
CLOCK and BMAL1 form a heterodimer that binds E-boxes in circadian gene promoters, regulating rhythmic expression.
Can E-box binding be targeted therapeutically?
Yes, small molecules like ME47 inhibit MYC-E-box binding and reduce tumor growth in preclinical models.
What are the different types of E-box motifs?
The canonical E-box is CANNTG, but flanking sequences and non-canonical motifs can influence binding affinity and specificity.
How does ZEB2 relate to E-box binding?
ZEB2 is a zinc finger E-box binding protein that drives age-associated B cell formation and is implicated in osteoarthritis [2,4].
What CRISPR models are available for E-box binding research?
EDITGENE offers knockout, point mutation, knock-in, and overexpression models for E-box factors, as well as CRISPR library screening [1,5].
Conclusion
E-box binding (GO:0070888) is a central regulatory process that controls gene expression programs in development, metabolism, and immunity. Its dysregulation contributes to cancer, fibrosis, and other diseases, making it a compelling target for therapeutic intervention. Advances in CRISPR genome editing and high-throughput sequencing have provided powerful tools to dissect the mechanisms and functions of E-box binding. EDITGENE supports this research with custom cell models and screening services, helping scientists translate discoveries into new treatments.
References
- 1. Pan Y et al.. 2023. E-box binding transcription factors in cancer.. Front Oncol 13:1223208 PMID: 37601651
- 2. Dai D et al.. 2024. The transcription factor ZEB2 drives the formation of age-associated B cells.. Science 383(6681):413-421 PMID: 38271512
- 3. Marri D et al.. 2023. Prediction of mammalian tissue-specific CLOCK-BMAL1 binding to E-box DNA motifs.. Sci Rep 13(1):7742 PMID: 37173345
- 4. Zhao GF et al.. 2023. Zinc finger E-box binding homebox 2 alleviated experimental osteoarthritis in rats.. Connect Tissue Res 64(4):323-336 PMID: 36880168
- 5. Jin H et al.. 2024. GTSE1-driven ZEB1 stabilization promotes pulmonary fibrosis through the epithelial-to-mesenchymal transition.. Mol Ther 32(11):4138-4157 PMID: 39342428
- 6. Lustig LC et al.. 2017. Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth.. Oncogene 36(49):6830-6837 PMID: 28806396
- 7. Allevato M et al.. 2017. Sequence-specific DNA binding by MYC/MAX to low-affinity non-E-box motifs.. PLoS One 12(7):e0180147 PMID: 28719624
- 8. Sun D et al.. 2021. Zinc‑finger E‑box‑binding homeobox 1 alleviates acute kidney injury by activating autophagy and the AMPK/mTOR pathway.. Mol Med Rep 23(6) PMID: 33846788
